Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults

Ejemplares similares

• A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
  por: Singla, Neil, et al.
  Publicado: (2017)
• APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
  por: Viscusi, Eugene R, et al.
  Publicado: (2019)
• APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
  por: Singla, Neil K., et al.
  Publicado: (2019)
• ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
  por: Bergese, Sergio D, et al.
  Publicado: (2019)
• Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
  por: Ok, Hwoe Gyeong, et al.
  Publicado: (2018)